AR045074A1 - Uso de cd164 soluble en desordenes inflamatorios y autoinmunes - Google Patents
Uso de cd164 soluble en desordenes inflamatorios y autoinmunesInfo
- Publication number
- AR045074A1 AR045074A1 ARP040102601A ARP040102601A AR045074A1 AR 045074 A1 AR045074 A1 AR 045074A1 AR P040102601 A ARP040102601 A AR P040102601A AR P040102601 A ARP040102601 A AR P040102601A AR 045074 A1 AR045074 A1 AR 045074A1
- Authority
- AR
- Argentina
- Prior art keywords
- soluble
- inflammatory
- auto
- immune disorders
- individual
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Reivindicación 1: Uso de un CD164 soluble, o una isoforma, muteína, proteína fusionada, derivado funcional, fragmento, fracción activa o sal del mismo, para la fabricación de un medicamento para tratamiento y/o prevención de desórdenes inflamatorios y/o autoinmunes. Reivindicación 11: Un método para inhibir la expresión de citocina en un individuo que comprende administrar a dicho individuo una composición que comprende un CD164 soluble. Reivindicación 13: Una composición farmacéutica que comprende un CD164 soluble, en presencia de uno o más excipientes farmacéuticamente aceptables, para el tratamiento de desórdenes inflamatorios y/o autoinmunes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03077316 | 2003-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045074A1 true AR045074A1 (es) | 2005-10-12 |
Family
ID=34112463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102601A AR045074A1 (es) | 2003-07-23 | 2004-07-22 | Uso de cd164 soluble en desordenes inflamatorios y autoinmunes |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20060257402A1 (es) |
| EP (1) | EP1646396A2 (es) |
| JP (1) | JP4705028B2 (es) |
| KR (1) | KR20060106810A (es) |
| CN (1) | CN1845752A (es) |
| AR (1) | AR045074A1 (es) |
| AU (1) | AU2004260835A1 (es) |
| BR (1) | BRPI0412243A (es) |
| CA (1) | CA2532870A1 (es) |
| EA (1) | EA009389B1 (es) |
| IL (1) | IL173197A0 (es) |
| NO (1) | NO20060781L (es) |
| RS (1) | RS20060023A (es) |
| WO (1) | WO2005011728A2 (es) |
| ZA (1) | ZA200600193B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1841447A1 (en) * | 2005-01-24 | 2007-10-10 | Laboratoires Serono S.A. | Use of soluble cd164 variants in inflammatory and/or autoimmune disorders |
| WO2008098734A1 (en) | 2007-02-12 | 2008-08-21 | Stefan Hansson | Diagnosis and treatment of preeclampsia |
| PL2638915T3 (pl) | 2008-07-18 | 2017-04-28 | A1M Pharma Ab | Medyczne zastosowanie zmiatacza wolnych rodników i antyoksydantu alfa-1-mikroglobuliny |
| US8392585B1 (en) * | 2011-09-26 | 2013-03-05 | Theranos, Inc. | Methods and systems for facilitating network connectivity |
| WO2022099695A1 (en) * | 2020-11-16 | 2022-05-19 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Cd164 fusion and uses thereof |
| CN114891107A (zh) * | 2022-05-12 | 2022-08-12 | 北京农学院 | 一种抗猪cd164l2单克隆抗体制备与应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2296792A1 (en) * | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| CA2438571A1 (en) * | 2001-02-12 | 2002-12-12 | Curagen Corporation | Novel proteins and nucleic acids encoding same |
-
2004
- 2004-07-22 AR ARP040102601A patent/AR045074A1/es not_active Application Discontinuation
- 2004-07-23 ZA ZA200600193A patent/ZA200600193B/xx unknown
- 2004-07-23 WO PCT/EP2004/051596 patent/WO2005011728A2/en active Application Filing
- 2004-07-23 CA CA002532870A patent/CA2532870A1/en not_active Abandoned
- 2004-07-23 AU AU2004260835A patent/AU2004260835A1/en not_active Abandoned
- 2004-07-23 BR BRPI0412243-7A patent/BRPI0412243A/pt not_active IP Right Cessation
- 2004-07-23 RS YUP-2006/0023A patent/RS20060023A/sr unknown
- 2004-07-23 EA EA200600314A patent/EA009389B1/ru not_active IP Right Cessation
- 2004-07-23 US US10/565,741 patent/US20060257402A1/en not_active Abandoned
- 2004-07-23 KR KR1020067000284A patent/KR20060106810A/ko not_active Application Discontinuation
- 2004-07-23 EP EP04766309A patent/EP1646396A2/en not_active Withdrawn
- 2004-07-23 CN CNA2004800253620A patent/CN1845752A/zh active Pending
- 2004-07-23 JP JP2006520839A patent/JP4705028B2/ja not_active Expired - Fee Related
-
2006
- 2006-01-17 IL IL173197A patent/IL173197A0/en unknown
- 2006-02-17 NO NO20060781A patent/NO20060781L/no not_active Application Discontinuation
-
2008
- 2008-12-22 US US12/341,490 patent/US8075894B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8075894B2 (en) | 2011-12-13 |
| EP1646396A2 (en) | 2006-04-19 |
| EA009389B1 (ru) | 2007-12-28 |
| JP2006528159A (ja) | 2006-12-14 |
| RS20060023A (en) | 2008-06-05 |
| NO20060781L (no) | 2006-03-17 |
| US20090285838A1 (en) | 2009-11-19 |
| IL173197A0 (en) | 2006-06-11 |
| BRPI0412243A (pt) | 2006-09-19 |
| JP4705028B2 (ja) | 2011-06-22 |
| WO2005011728A3 (en) | 2005-06-02 |
| EA200600314A1 (ru) | 2006-06-30 |
| CA2532870A1 (en) | 2005-02-10 |
| ZA200600193B (en) | 2007-04-25 |
| CN1845752A (zh) | 2006-10-11 |
| US20060257402A1 (en) | 2006-11-16 |
| KR20060106810A (ko) | 2006-10-12 |
| AU2004260835A1 (en) | 2005-02-10 |
| WO2005011728A2 (en) | 2005-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116215T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
| CO5251419A1 (es) | Composiciones nanoparticuladas de eplerenona | |
| BR0109779A (pt) | Soluções moleculares hidrofìlicas dispersas de carvedilol | |
| AR062775A1 (es) | Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamento | |
| BRPI0415649A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
| NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
| DE60332358D1 (de) | Protease-resistente modifizierte interferon alpha polypeptide | |
| AR039103A1 (es) | Uso de inhibidores de il-18 para el tratamiento y/o prevencion de enfermedades vasculares perifericas | |
| EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
| BR0305628A (pt) | Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso | |
| CO6160321A2 (es) | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo | |
| ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
| EA200602137A1 (ru) | Гидрогелевые препараты интерферона | |
| AR040709A1 (es) | Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion | |
| ATE364595T1 (de) | Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| ECSP078014A (es) | Regimen de dosificacion para prasugrel | |
| BR112023000270A2 (pt) | Composto, composição farmacêutica, e, peptídeo | |
| AR052567A1 (es) | Combinacion de bambuterol e inhibidor de integrina | |
| AR056517A1 (es) | Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa | |
| AR045074A1 (es) | Uso de cd164 soluble en desordenes inflamatorios y autoinmunes | |
| ATE413187T1 (de) | Pharmazeutische zusammensetzungen mit interferon- tau |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |